viewProactive Group

Celldex's triple-negative breast cancer drug fails in clinical trial; shares plummet

The company plans to discontinue its research into glembatumumab vedotin

Picture of a woman undergoing chemotherapy
The company is now shaking up its pipeline, which consists of five drug candidates

Shares of Celldex Therapeutics Inc (NASDAQ:CLDX)  plunged after the company said that the phase 2b trial for its treatment of triple-negative breast cancer has failed.

The stock shed 64% to trade at US$0.78 in early afternoon trading.

The company reported that its drug candidate -- glembatumumab vedotin known as glemba -- which was taken by patients with metastatic triple-negative breast cancer -- did not meet its primary end point of improving progression-free survival in its phase 2b clinical trial. Celldex also said that there is no advantage for glemba in key secondary endpoints.

The biopharmaceutical firm plans to discontinue its glemba program and it is shaking up its pipeline, which consists of five drug candidates that are involved in ongoing clinical studies.

“Triple-negative breat cancer is a very difficult disease to treat, and we are extremely disappointed for patients that the METRIC study was not successful,” said Anthony Marucci, the co-founder and chief executive officer of Celldex. “In line with this, we are evaluating our operational and workforce needs to extend our financial resources and direct them to continued pipeline advancement. Once we solidify these plans, we intend to update investors.”

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Helix Technologies following up strong 2019 with success in 2020

Helix Technologies (OTCQB: HLIX) President of Data Services Garvis Toler joined Steve Darling from Proactive Vancouver to discuss the company releasing their 2019 financial numbers which were very strong and also what milestones they hit to close the year.  Toler also told Proactive...

16 hours, 56 minutes ago

2 min read